Oncodesign Precision Medicine

Research Oncodesign Precision Medicine (ALOPM) on Bullrun: market cap EUR 6.63M, P/E 1.2. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerALOPM
• ExchangePA
• CountryFrance
• SectorHealthcare
• IndustryBiotechnology
• CurrencyEUR
• Market capEUR 6.63M
• P/E1.2
• Financial periodFY2024
• RevenueEUR 207.04K
• Revenue growth-80.7%
• Net income-EUR 7.21M
• Gross margin-3039.8%

Valuation Snapshot

latest market cap is EUR 6.63M; P/E is 1.2.

About Oncodesign Precision Medicine

Oncodesign Precision Medicine Société anonyme, a biopharmaceutical company, engages in the precision medicine business. The company's product pipeline consist of OPM-101, a RIPK2 inhibitor for the treatment of inflammatory bowel disease and immuno-oncology; OPM-102 to treat cancer; and OPM-201, a LRRK2 inhibitor for the treatment of Parkinson's disease.

Frequently asked questions

What is Oncodesign Precision Medicine's market cap?

Oncodesign Precision Medicine's market capitalization is EUR 6.63M.

What is Oncodesign Precision Medicine's P/E ratio?

Oncodesign Precision Medicine's price-to-earnings (P/E) ratio is 1.2.

What does Oncodesign Precision Medicine do?

Oncodesign Precision Medicine Société anonyme, a biopharmaceutical company, engages in the precision medicine business. The company's product pipeline consist of OPM-101, a RIPK2 inhibitor for the treatment of inflammatory bowel disease and immuno-oncology; OPM-102 to treat cancer;